Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
This cost-effective tool will be of immense benefit to other high burden countries as well.
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
The curriculum has been curated for General Physicians working in Clinikk
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Multiples is the first private equity (PE) investor in the company
Quantib Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
The new hospital is expected to open by March'24
Subscribe To Our Newsletter & Stay Updated
